AbbVie (ABBV) : Traders are bullish on AbbVie (ABBV) as it has outperformed the S&P 500 by a wide margin of 1.19% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.04%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.47% in the last 1 week, and is up 3.71% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
AbbVie (NYSE:ABBV): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $66.15 and $66.12 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $66.60. The buying momentum continued till the end and the stock did not give up its gains. It closed at $66.54, notching a gain of 0.67% for the day. The total traded volume was 5,045,559 . The stock had closed at $66.10 on the previous day.
The stock has recorded a 20-day Moving Average of 2.92% and the 50-Day Moving Average is 6.48%. AbbVie Inc. is up 7.38% in the last 3-month period. Year-to-Date the stock performance stands at 15.6%.
AbbVie (ABBV) : 13 investment research analysts covering AbbVie (ABBV) have an average price target of $72 for the near short term. The highest target price given by the Brokerage Firm to the stock is $90 and the lowest target is $47 for the short term. Analysts expect the variance to be within $10.71 of the average price.
AbbVie Inc. (AbbVie) is a global, research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Companys products are focused on treating conditions, such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohns disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinsons disease; complications associated with chronic kidney disease and cystic fibrosis, and other health conditions, such as low testosterone. AbbVie also has a pipeline of new medicines, including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties, such as immunology, virology/liver disease, oncology, renal disease, neurological diseases and womens health. The Companys product portfolio includes HUMIRA, HCV products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products.